Florida Blue

An Independent Licensee of the
Blue Cross and Blue Shield Association

October 2018

Repatha is Our New Preferred PCSK9 Inhibitor for Commercial Plans

Repatha is our exclusive proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor for treatment of high cholesterol not controlled with statin treatment, effective October 1, 2018. Praluent was excluded from coverage effective October 1, for **new patients** beginning PCSK9 inhibitor treatment.

This change applies to commercial plans. It does not apply to Medicare plans, including BlueMedicare℠ PPO and HMO plans.

We've updated our clinical guidelines for the prior authorization review of Repatha. This includes:

- Removing the requirement for Zetia (ezetimibe) step therapy
- Reducing the pre-PCSK9 treatment LDL-C requirement to 70 mg/dL or greater for all indications
- Increasing the duration of therapy for up to one year

How This Affects You

For patients initiating new treatment with a PCSK9 inhibitor, prescribe Repatha if, in your clinical judgement, Repatha is appropriate for your patient. Otherwise, you will be contacted by the pharmacy to determine whether the patient can be treated with Repatha. The standard prior authorization process for requesting review of Repatha and submitting required documentation is still required for new patients.

For patients currently receiving Praluent, we will honor current authorizations and coordinate the prior authorization transition to Repatha where appropriate. Most importantly, you will be contacted by the specialty pharmacy determine whether Repatha is appropriate for your patient.

For more information, contact Prime Therapeutics' Clinical Review at **888-271-3183**.